Tavaborole has an elimination half-life of 28.5 hours, a maximum concentration of 5.17 ng/mL after two weeks of daily use, and takes 8 days to reach the maximum concentration. Society and culture
Economics
Tavaborole began phase III clinical trials in December 2010 and was approved by the US FDA in July 2014.Originally developed by Anacor, it is now marketed in the United States by Novartis subsidiary Sandoz. Anacor was paid US$65 million and also entered into a profit sharing scheme for future sales. A 10 mL bottle of a 5% solution of tavaborole will cost the patient without insurance about $1,356. See also
Crisaborole – a structurally related topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema)

References
External links
"Tavaborole". Drug Information Portal. U.S. National Library of Medicine.
Prurigo gestationis is an eruption consisting of pruritic, excoriated papules of the proximal limbs and upper trunk, most often occurring between the 20th and 34th week of gestation.The exact etiology is unknown, but it is considered likely to be a flareup of atopic dermatitis during pregnancy.It is sometimes considered to be a term encompassing Besniers prurigo gestationis and other conditions.It is sometimes considered a diagnosis of exclusion. See also
Dermatoses of pregnancy
Ernest Henri Besnier
List of cutaneous conditions


== References ==